Drugs / B003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03953833 | Apr 2019 → Jan 2023 | HER2 positive breast carcinoma | Shanghai Pharmaceuticals Holding Co., Ltd | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-03-22 | Sichuan Biokin Pharmaceutical Co., Ltd. | 四川百利天恒药业股份有限公司关于自愿披露“BL-B01D1＋化疗”及“BL-B01D1+SI-B003±化疗”获得II期临床试验批准通知书的公告 cninfo.com.cn ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03953833 ↗ |
| Modality | Monoclonal antibody | “humanized monoclonal antibody” NCT03953833 ↗ |
| Route | Intravenous | “Usage: Intravenous infusion” NCT03953833 ↗ |